Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks | Drug and Therapeutics Bulletin

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Browse

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Editorial

Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks

Online download statistics by month:

Online download statistics by month: February 2020 to April 2023

	Abstract	Full	Pdf
Feb 2020	718	41	24
Mar 2020	949	28	24
Apr 2020	242	4	1
May 2020	176	5	4
Jun 2020	80	2	1
Jul 2020	42	3	2
Aug 2020	78	3	1
Sep 2020	73	3	1
Oct 2020	59	3	1
Nov 2020	96	2	2
Dec 2020	109	0	0
Jan 2021	119	2	1
Feb 2021	114	1	1
Mar 2021	176	0	0
Apr 2021	183	0	0
May 2021	82	1	1
Jun 2021	2	0	0
Jul 2021	8	1	0
Aug 2021	5	0	0
Sep 2021	5	0	0
Oct 2021	96	0	0
Nov 2021	82	1	1
Dec 2021	63	3	2
Jan 2022	66	5	0
Feb 2022	42	1	0
Mar 2022	52	0	0
Apr 2022	41	0	0
May 2022	83	0	1
Jun 2022	55	0	0
Jul 2022	69	1	0
Aug 2022	67	0	0
Sep 2022	56	1	0
Oct 2022	59	1	1
Nov 2022	35	0	1
Dec 2022	26	0	0
Jan 2023	22	0	0
Feb 2023	59	1	1
Mar 2023	16	0	0
Apr 2023	42	0	1
Total	4347	113	72